H1’s Post

We thank BioPharma-Reporter for their coverage of our collaboration with Skye Bioscience Inc.! Together, we're leveraging our FDA 510(k)-cleared Dreem sleep EEG headband to characterize changes in sleep quality in obesity and sleep apnea. This latest article covers an in-depth Q&A about Skye's upcoming CBEYOND™ Phase 2 trial of Nimacimab, a CB1 inhibitor. Beacon will be deploying Dreem in a sub-study of CBEYOND, measuring multiple nights of sleep across the trial where enrolled participants are taking Nimacimab alone or in combination with semaglutide. The insights gathered from characterizing changes in objective sleep quality across the treatment period may enable Skye to better target patient subgroups and optimize treatments for obesity, OSA and beyond. Read the full article below: https://lnkd.in/g9Ns77Aa Reach out to learn more about working together for your clinical trials: https://beacon.bio/contact #skye #beacon #collaboration #CB1 #EEG #Dreem #OSA #obesity #GLP1

Suggested read here for sleep medicine clinicians ⬇️ The PAP-RES algorithm is a new approach to CPAP therapy. The algorithm focuses on identifying OSA phenotypes, which are distinct groups of individuals with OSA who have different symptom burdens and cardiovascular vulnerability levels. This approach aims to personalize CPAP therapy based on the individual's phenotype, leading to better outcomes and a more effective treatment plan. Michael McEwan Katie Simpson Anthony Warren Kuldip Madar Liam Ions Charlotte Gough AbdelKebir SABIL, PhD Sefam Medical UK Sefam SEFAM INDIA Sefam Medical South Europe

The #BMC #G3 A20 device, equipped with SmartA/C technology, delivers an enhanced CPAP therapy experience for individuals suffering from Obstructive Sleep Apnea (#OSA). The intelligent #SmartC feature optimizes treatment pressure every 5 effective treatment days, based on the obstructive Apnea-Hypopnea Index (#AHI) and Snoring Index (#SNI), ensuring consistent therapeutic effectiveness. This adaptive approach minimizes the need for frequent clinical adjustments, supporting long-term patient compliance with CPAP therapy. Additionally, the #SmartA function introduces an optimal starting pressure, designed to mitigate residual events at the onset of therapy that may occur due to inadequate pressure levels. It further refines the minimum and maximum pressures within the treatment plan, depending on P95 and P50 data, over a moving 5-day period. This dynamic adjustment leads to more efficient and personalized CPAP therapy, enhancing overall treatment outcomes.

Good coverage on a potential new oral treatment for sleep apnea which affects 30-40MM people in the US. The current standard treatment is to sleep with a cumbersome and uncomfortable device, which patients are frequently not compliant with. Topline data from Phase III trials are expected in 2025 but phase II data showed clinically meaningful improvements in certain endpoints. Trial results, if positive, could highlight patient segments which benefit the most from the treatment. Obvious commercial questions relate to changes in diagnosis rate, drug treatment rate, compliance, and price. https://lnkd.in/eW9uhbAn #sleepapnea #biotech #insights

Are you leaving patient referrals on the table? Your next big sleep apnea case could be just one lunch away. This week's More Than Teeth🦷 newsletter unveils the secret sauce to building win-win alliances with referring physicians. Did you know: 1️⃣ A simple 2-minute elevator pitch customized for each specialty can dramatically boost referrals. 2️⃣ Offering complimentary consultations can remove barriers and increase patient flow. From hosting "Lunch and Learns" to crafting the perfect referral form, we're breaking down 8 actionable strategies to turn physicians into your biggest advocates. Dentists, what's your most successful tactic for building referral relationships? Share your wins (or challenges) below! Hungry for more? Dive into the full edition of More Than Teeth🦷 for a step-by-step guide to referral mastery. Your next game-changing partnership is just a read away!"

More doctors prescribe pharmaceuticals for sleep issues than anything else according to our Sleep Survey. Here is some other things the pros suggest according to PwP and Care Partners. Details on the survey: https://lnkd.in/dSm-XNpT

Engaging CPAP Alternative Patients: Essential Strategies for Connection 🤝🛏️ Dive into the world of CPAP alternatives and learn how to effectively reach and communicate with patients seeking different sleep apnea treatment options. Discover key techniques for understanding their needs, providing tailored advice, and building lasting relationships. Ideal for healthcare professionals looking to expand their patient base in the realm of sleep medicine. Master the Art of Connecting with CPAP Alternative Patients ➡️ Learn More: https://lnkd.in/dmaGFQcj #CPAPAlternatives #PatientEngagement #SleepHealthProfessionals

It’s #SleepApneaEducationWeek! #DYK: Most people diagnosed with obstructive #sleepapnea are prescribed positive air pressure therapy devices such as continuous positive airway pressure, or CPAP, but fewer than half continue to use the device long-term, leaving a significant population untreated, undertreated and at risk. Apnimed has made finding new oral medications for #OSA a priority and is working to transform the way OSA is treated by focusing on the underlying cause of the condition. Learn more about our research at: https://bit.ly/4afvAkG Alliance of Sleep Apnea Partners #sleepdisorders #drugdiscovery #innovation

Inspire Medical has received FDA approval for its innovative Inspire V neurostimulator designed to treat obstructive sleep apnea. This next-generation device delivers gentle electrical stimulation to the hypoglossal nerve, helping to control tongue muscles, and comes equipped with a Bluetooth remote for both patients and physicians. A full commercial launch is anticipated in 2025, following a soft launch late next year. Reflecting on this breakthrough, I am reminded of how such technological advancements can completely redefine patient experiences. As individuals continue to seek effective solutions for sleep disorders, innovations like Inspire V could lead to better outcomes and improve quality of life for many. How do you think advancements in medical technology will shape the future of patient care? 🤔 The medtech industry has so much potential to evolve and thrive, just like Inspire Medical which recently reported a 30% year-over-year revenue growth in Q2 2024. This is just the beginning — we can only anticipate what amazing developments lie ahead. #MedTech #InspireMedical #SleepApnea #Innovation #HealthcareTechnology

Inspire Recalls Key Component of Neurostimulator Therapy for OSA https://lnkd.in/g4Ps59m8